公司概述
Aurora Cannabis Inc. engages in the production, distribution, and sale of pharmaceutical-grade cannabis and cannabis-derivative products, operating primarily within the Canadian market and expanding internationally. The company operates within the Healthcare sector, specifically under the industry classification of Drug Manufacturers - Specialty & Generic, which implies a focus on specialized medicinal compounds rather than consumer recreational goods. Aurora Cannabis Inc. currently holds a market capitalization of $197.35M and reports trailing twelve-month revenue of $373.12M, while the specific employee count is listed as N/A in available data. These valuation and revenue figures indicate that the company maintains a significant operational footprint within a niche market, possessing a market cap that reflects its specialized manufacturing capabilities despite the absence of traditional employee metrics.
财务健康
The company recorded revenue of $373.12M for the trailing twelve months, yet it posted a net income of -$83,512,000 and an EBITDA of -$32,735,000, revealing a substantial gap between top-line sales and profitability. This disparity indicates a heavy cost structure where operating expenses significantly erode the bottom line before taxes and interest. However, the entity generated positive free cash flow of $11.86M, which suggests a degree of financial flexibility to fund operations or strategic initiatives despite the accounting losses. The gross margin stands at 36.0%, indicating that the company retains over a third of sales revenue after direct production costs, while the operating margin of 2.3% reflects tight control over overhead expenses relative to total revenue. The profit margin is negative at -22.5%, confirming that net income is heavily impacted by non-operating factors or significant tax and interest burdens. In terms of liquidity and leverage, the company holds $108.45M in cash against $101.00M in total debt, resulting in a debt-to-equity ratio of 17.79, which points to a highly leveraged balance sheet where equity capital is minimal compared to liabilities. The current ratio of 3.06 indicates strong short-term liquidity, as the company possesses more than three times the current assets necessary to cover its short-term obligations. Furthermore, the return on equity is -15.5% and the return on assets is -4.4%, metrics that reveal management has yet to generate positive returns on the capital deployed to run the business, highlighting challenges in capital efficiency.
估值评估
Aurora Cannabis Inc. exhibits a forward P/E of -31.64, while the trailing P/E (TTM) is N/A due to negative earnings, a combination that implies earnings are currently negative and future profitability assumptions are required to determine a meaningful multiple. The price-to-book ratio is 0.51, indicating that the market values the company at roughly half of its net asset value, suggesting a market premium is absent and the stock may be trading at a discount to its book value. Alternative valuation metrics such as the price-to-sales ratio of 0.53 and an EV/EBITDA of -6.76 suggest that investors are pricing the stock based on revenue generation rather than current earnings power or cash flow multiples. The stock's price range over the last year has fluctuated between a 52-week low of $3.07 and a high of $6.67, providing a clear band for historical price discovery. While the current trading price is not explicitly provided to calculate an exact percentage, the wide range between $3.07 and $6.67 demonstrates significant intrayear volatility. The beta of 1.32 indicates that the stock's price volatility is 32% higher than the broader market, meaning the asset moves with greater sensitivity to market swings than large-cap financials.
Growth & Income
Aurora Cannabis Inc. achieved a revenue growth rate of 6.8% year-over-year, whereas earnings growth was -94.7% year-over-year, indicating that earnings are shrinking at a much faster pace than revenue, which implies deteriorating profitability or margin compression despite sales expansion. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available earnings back into the business or uses cash reserves to manage its debt and operations. This growth and income profile characterizes a capital-intensive growth stage where the company prioritizes revenue expansion and market share consolidation over returning cash to shareholders. The overall profile reflects a company balancing top-line growth initiatives with the financial pressure of maintaining a highly leveraged capital structure in a specialized healthcare sector.